Sclerostin: a possible target for the management of cancer-induced bone disease

Bibliography

• Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010;87:99-107
   PubMed Web of Science ®Google Scholar
• Brunkow ME, Gardner JC, van Ness J, Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68:577-89
   PubMed Web of Science ®Google Scholar
• Balemans W, Patel N, Ebeling M, Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002;39:91-7
   PubMed Web of Science ®Google Scholar
• Stein SA, Witkop C, Hill S, Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology 1983;33:267-77
   PubMed Web of Science ®Google Scholar
• van Lierop AH, Hamdy NA, Hamersma H, Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 2011;26:2804-11
   PubMed Web of Science ®Google Scholar
• Coleman RE, Lipton A, Roodman GD, Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 2010;36:615-20
   PubMed Web of Science ®Google Scholar
• Langley RR, Fidler IJ. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011;128:2527-35
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005;16:1223-31
   PubMed Web of Science ®Google Scholar
• Ohyama Y, Nifuji A, Maeda Y, Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis. Endocrinology 2004;145:4685-92
   PubMed Web of Science ®Google Scholar
• Balemans W, Ebeling M, Patel N, Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537-43
   PubMed Web of Science ®Google Scholar
• Poole KE, van Bezooijen RL, Loveridge N, Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005;19:1842-4
   PubMed Web of Science ®Google Scholar
• Bellido T, Ali AA, Gubrij I, Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146:4577-83
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-61
   PubMed Web of Science ®Google Scholar
• Rochefort GY, Pallu S, Benhamou CL. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int 2010;21:1457-69
   PubMed Web of Science ®Google Scholar
• Sutherland MK, Geoghegan JC, Yu C, Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004;35:448-54
   PubMed Web of Science ®Google Scholar
• Irie K, Ejiri S, Sakakura Y, Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem 2008;56:561-7
   PubMedGoogle Scholar
• Sutherland MK, Geoghegan JC, Yu C, Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004;35:828-35
   PubMed Web of Science ®Google Scholar
• Winkler DG, Sutherland MK, Geoghegan JC, Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003;22:6267-76
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Y, Kang H, Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280:19883-7
   PubMed Web of Science ®Google Scholar
• Ellies DL, Viviano B, McCarthy J, Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006;21:1738-49
   PubMedGoogle Scholar
• Hens JR, Wilson KM, Dann P, TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J Bone Miner Res 2005;20:1103-13
   PubMed Web of Science ®Google Scholar
• Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone 2008;42:606-15
   PubMed Web of Science ®Google Scholar
• Winkler DG, Yu C, Geoghegan JC. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 2004;279:36293-8
   PubMed Web of Science ®Google Scholar
• Craig TA, Bhattacharya R, Mukhopadhyay D, Kumar R. Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem Biophys Res Commun 2010;392:36-40
   Google Scholar
• Devarajan-Ketha H, Craig TA, Madden BJ, The sclerostin-bone protein interactome. Biochem Biophys Res Commun 2012;417:830-5
   PubMed Web of Science ®Google Scholar
• Wergedal JE, Veskovic K, Hellan M, Patients with van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 2003;88:5778-83
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Anastasilakis AD, Bratengeier C, Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int 2012;23:1171-6
   PubMedGoogle Scholar
• Voskaridou E, Christoulas D, Plata E, High circulating sclerostin correlates with bone mineral density and indicates high osteocyte activity in patients with thalassemia-associated osteoporosis. Horm Metab Res 2012; In press
   Google Scholar
• Gaudio A, Pennisi P, Bratengeier C, Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010;95:2248-53
   PubMed Web of Science ®Google Scholar
• Terpos E, Fragiadaki K, Konsta M, Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:921-5
   PubMed Web of Science ®Google Scholar
• Cejka D, Herberth J, Branscum AJ, Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011;6:877-82
   PubMed Web of Science ®Google Scholar
• Cejka D, Jager-Lansky A, Kieweg H, Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012;27:226-30
   PubMed Web of Science ®Google Scholar
• Modder UI, Hoey KA, Amin S, Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011;26:373-9
   PubMed Web of Science ®Google Scholar
• Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010;95:1991-7
   PubMed Web of Science ®Google Scholar
• Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther 2010;10:658-64
   PubMed Web of Science ®Google Scholar
• Chikazawa N, Tanaka H, Tasaka T, Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010;30:2041-8
   PubMed Web of Science ®Google Scholar
• Scholer-Dahirel A, Schlabach MR, Loo A, Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. Proc Natl Acad Sci USA 2011;108:17135-40
   PubMed Web of Science ®Google Scholar
• Ettenberg SA, Charlat O, Daley MP, Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 2010;107:15473-8
   PubMed Web of Science ®Google Scholar
• Lucero OM, Dawson DW, Moon RT, Chien AJ. A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep 2010;12:314-18
   PubMed Web of Science ®Google Scholar
• Svedlund J, Auren M, Sundstrom M, Aberrant WNT/beta-catenin signaling in parathyroid carcinoma. Mol Cancer 2010;9:294
   Google Scholar
• Wend P, Holland JD, Ziebold U, Birchmeier W. Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 2010;21:855-63
   PubMed Web of Science ®Google Scholar
• El Wakil A, Lalli E. The Wnt/beta-catenin pathway in adrenocortical development and cancer. Mol Cell Endocrinol 2011;332:32-7
   PubMed Web of Science ®Google Scholar
• Lavergne E, Hendaoui I, Coulouarn C, Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active beta-catenin. Oncogene 2011;30:423-33
   Google Scholar
• Liu C, Tu Y, Sun X, Wnt/beta-catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin Exp Med 2011;11:105-12
   PubMed Web of Science ®Google Scholar
• Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011;8:97-106
   PubMed Web of Science ®Google Scholar
• Yu X, Wang Y, Degraff DJ, Wnt/beta-Catenin activation promotes prostate tumor progression in a mouse model. Oncogene 2011;30:1868-79
   PubMed Web of Science ®Google Scholar
• Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010;37(Suppl 2):S15-29
   PubMedGoogle Scholar
• Terpos E, Dimopoulos MA. Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. Cancer Immunol Immunother 2011;60:305-17
   Google Scholar
• Sterling JA, Edwards JR, Martin TJ, Mundy GR. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 2011;48:6-15
   PubMed Web of Science ®Google Scholar
• Bu G, Lu W, Liu CC, Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 2008;123:1034-42
   PubMed Web of Science ®Google Scholar
• Sevetson B, Taylor S, Pan Y. Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem 2004;279:13849-58
   PubMed Web of Science ®Google Scholar
• Mendoza-Villanueva D, Zeef L, Shore P. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res 2011;13(5):R106
   Google Scholar
• Voorzanger-Rousselot N, Goehrig D, Journe F, Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007;97:964-70
   PubMed Web of Science ®Google Scholar
• Yuen HF, Chan YP, Cheung WL, The prognostic significance of BMP-6 signaling in prostate cancer. Mod Pathol 2008;21:1436-43
   Google Scholar
• Lu W, Liu CC, Thottassery JV, Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells. Biochemistry 2010;49:4635-43
   Google Scholar
• Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol 2011;29:1907-15
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94
   PubMed Web of Science ®Google Scholar
• Politou MC, Heath DJ, Rahemtulla A, Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119:1728-31
   PubMed Web of Science ®Google Scholar
• Oshima T, Abe M, Asano J, Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005;106:3160-5
   PubMed Web of Science ®Google Scholar
• Brunetti G, Oranger A, Mori G, Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann NY Acad Sci 2011;1237:19-23
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Katodritou E, Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 2011; published on line 2 November 2011; doi: 10.1002/ijc.27342.
   Google Scholar
• Terpos E, Christoulas D, Gkotzamanidou M, Circulating levels of the Wnt inhibitors dickkopf-1 and sclerostin in different phases of multiple myeloma: alterations post-therapy with lenalidomide and dexamethasone with or without bortezomib [abstract]. ASH Annual Meeting Abstracts. Blood 2010;116:2963
   Google Scholar
• Eda H, Santo L, Cirstea DD, Increased sclerostin secretion in multiple myeloma results in stimulation of osteoclastogenesis and inhibition of osteoblastogenesis [abstract]. ASH Annual Meeting Abstracts. Blood 2011;118:1819
   Google Scholar
• Bida JP, Kyle RA, Therneau TM, Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009;84:685-93
   PubMed Web of Science ®Google Scholar
• Li X, Warmington KS, Niu QT, Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010;25:2647-56
   PubMed Web of Science ®Google Scholar
• Tian X, Setterberg RB, Li X, Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 2010;47:529-33
   Google Scholar
• Li X, Ominsky MS, Warmington KS, Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24:578-88
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Vlasseros F, Jolette J, Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25:948-59
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Li C, Li X, Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011;26:1012-21
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26
   PubMed Web of Science ®Google Scholar